NL300779I2 - Combinatie van a) olodaterol, het individuele optische R-isomeer daarvan, mengsels van individuele enantiomeren of racematen, zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, desgewenst in de vorm van solvaten en/of hydraten, en b) een tiotropiumzout; in het bijzonder combinatie van a) olodaterol en zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, en b) tiotropiumbromide, desgewenst in de vorm van een solvaat en/of hydraat; meer in het bijzonder combinatie van a) olodaterolhydrochloride en b) tiotropiumbromide, desgewenst in de vorm van het monohydraat - Google Patents

Combinatie van a) olodaterol, het individuele optische R-isomeer daarvan, mengsels van individuele enantiomeren of racematen, zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, desgewenst in de vorm van solvaten en/of hydraten, en b) een tiotropiumzout; in het bijzonder combinatie van a) olodaterol en zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, en b) tiotropiumbromide, desgewenst in de vorm van een solvaat en/of hydraat; meer in het bijzonder combinatie van a) olodaterolhydrochloride en b) tiotropiumbromide, desgewenst in de vorm van het monohydraat

Info

Publication number
NL300779I2
NL300779I2 NL300779C NL300779C NL300779I2 NL 300779 I2 NL300779 I2 NL 300779I2 NL 300779 C NL300779 C NL 300779C NL 300779 C NL300779 C NL 300779C NL 300779 I2 NL300779 I2 NL 300779I2
Authority
NL
Netherlands
Prior art keywords
optionally
olodaterol
combination
acid addition
addition salts
Prior art date
Application number
NL300779C
Other languages
English (en)
Dutch (nl)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300779(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102004019540A external-priority patent/DE102004019540A1/de
Priority claimed from DE102004052987A external-priority patent/DE102004052987A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NL300779I2 publication Critical patent/NL300779I2/nl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
NL300779C 2004-04-22 2015-12-01 Combinatie van a) olodaterol, het individuele optische R-isomeer daarvan, mengsels van individuele enantiomeren of racematen, zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, desgewenst in de vorm van solvaten en/of hydraten, en b) een tiotropiumzout; in het bijzonder combinatie van a) olodaterol en zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, en b) tiotropiumbromide, desgewenst in de vorm van een solvaat en/of hydraat; meer in het bijzonder combinatie van a) olodaterolhydrochloride en b) tiotropiumbromide, desgewenst in de vorm van het monohydraat NL300779I2 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102004019540A DE102004019540A1 (de) 2004-04-22 2004-04-22 Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
DE102004052987A DE102004052987A1 (de) 2004-11-03 2004-11-03 Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
EP05002496 2005-02-07
PCT/EP2005/004073 WO2005102349A1 (de) 2004-04-22 2005-04-18 Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen
EP05739576A EP1781298B1 (de) 2004-04-22 2005-04-18 Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen

Publications (1)

Publication Number Publication Date
NL300779I2 true NL300779I2 (nl) 2017-11-02

Family

ID=34966478

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300779C NL300779I2 (nl) 2004-04-22 2015-12-01 Combinatie van a) olodaterol, het individuele optische R-isomeer daarvan, mengsels van individuele enantiomeren of racematen, zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, desgewenst in de vorm van solvaten en/of hydraten, en b) een tiotropiumzout; in het bijzonder combinatie van a) olodaterol en zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, en b) tiotropiumbromide, desgewenst in de vorm van een solvaat en/of hydraat; meer in het bijzonder combinatie van a) olodaterolhydrochloride en b) tiotropiumbromide, desgewenst in de vorm van het monohydraat

Country Status (33)

Country Link
EP (2) EP2422786B1 (instruction)
JP (1) JP2007533683A (instruction)
KR (2) KR20130049840A (instruction)
AR (1) AR049262A1 (instruction)
AT (1) ATE539754T1 (instruction)
AU (1) AU2005235419B2 (instruction)
BE (1) BE2015C065I2 (instruction)
BR (1) BRPI0510080B8 (instruction)
CA (1) CA2559699C (instruction)
CY (3) CY1113890T1 (instruction)
DK (2) DK2422786T3 (instruction)
EA (1) EA013157B1 (instruction)
EC (1) ECSP066947A (instruction)
ES (2) ES2380370T3 (instruction)
FI (1) FIC20170005I1 (instruction)
FR (1) FR16C0029I2 (instruction)
HU (1) HUS1500058I1 (instruction)
IL (2) IL177685A (instruction)
LT (1) LTC1781298I2 (instruction)
LU (1) LU93066I2 (instruction)
MY (1) MY148945A (instruction)
NL (1) NL300779I2 (instruction)
NO (2) NO337714B1 (instruction)
NZ (1) NZ550797A (instruction)
PE (1) PE20060462A1 (instruction)
PL (2) PL2422786T3 (instruction)
PT (2) PT2422786E (instruction)
SG (1) SG152237A1 (instruction)
SI (2) SI1781298T1 (instruction)
TW (2) TWI372056B (instruction)
UY (1) UY28861A1 (instruction)
WO (1) WO2005102349A1 (instruction)
ZA (1) ZA200606624B (instruction)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US7923455B2 (en) * 2005-01-28 2011-04-12 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
WO2006087316A1 (en) * 2005-02-16 2006-08-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising anticholinergics and etiprednol
ES2530991T3 (es) 2005-08-15 2015-03-09 Boehringer Ingelheim Int Procedimiento para la obtención de betamiméticos
TWI389692B (zh) 2005-10-10 2013-03-21 Boehringer Ingelheim Int 用以吸入β-共效劑的氣溶膠調配物
US20070086957A1 (en) * 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
CA2627982C (en) * 2005-11-10 2013-09-10 Nicholas S. Bodor Soft anticholinergic esters
JP2009526817A (ja) * 2006-02-16 2009-07-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療用医薬組成物
US20090324510A1 (en) 2006-08-07 2009-12-31 Boehringer Ingelheim International Gmbh Drug combinations for the treatment of respiratory tract diseases
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
US20100099651A1 (en) * 2006-10-26 2010-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EA019709B1 (ru) 2008-02-07 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Спирогетероциклы и их применение в качестве лекарственных средств
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US20120135969A1 (en) * 2008-11-27 2012-05-31 Boehringer Ingelheim International Gmbh Novel powdered crystalline medicines for inhalation
WO2014016548A2 (en) * 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
EP2906218B1 (en) 2012-10-09 2016-12-14 Boehringer Ingelheim International GmbH Beta-2-adrenoceptor agonist for the treatment of cough

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
CH672600A5 (instruction) 1985-07-30 1989-12-15 Glaxo Group Ltd
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
JP2003533448A (ja) * 2000-04-27 2003-11-11 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規持続性ベータ擬似剤、その製造方法及びその医薬としての使用
CA2425539C (en) 2000-10-12 2007-04-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline monohydrate, processes for the preparation thereof and the use thereof for preparing a pharmaceutical composition
KR100971616B1 (ko) 2001-06-22 2010-07-22 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
DE10230751A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern
DE10246374A1 (de) * 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253282A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung

Also Published As

Publication number Publication date
NO2016022I2 (no) 2016-12-01
EP2422786B1 (de) 2014-08-13
TW201231055A (en) 2012-08-01
BRPI0510080B1 (pt) 2020-08-18
AU2005235419A1 (en) 2005-11-03
PL1781298T3 (pl) 2012-06-29
UY28861A1 (es) 2005-11-30
WO2005102349A1 (de) 2005-11-03
ES2380370T3 (es) 2012-05-11
EA200601846A1 (ru) 2007-04-27
NZ550797A (en) 2010-08-27
KR20070015592A (ko) 2007-02-05
ATE539754T1 (de) 2012-01-15
CY1115719T1 (el) 2017-01-25
IL177685A0 (en) 2006-12-31
ES2523518T3 (es) 2014-11-26
PT1781298E (pt) 2012-02-03
DK2422786T3 (da) 2014-11-17
PL2422786T3 (pl) 2015-02-27
LTC1781298I2 (lt) 2018-09-25
AR049262A1 (es) 2006-07-12
TWI372056B (en) 2012-09-11
CA2559699C (en) 2012-06-19
PT2422786E (pt) 2014-11-12
AU2005235419B2 (en) 2010-11-04
NO2016022I1 (no) 2016-12-01
NO337714B1 (no) 2016-06-06
PL1781298T4 (pl) 2017-07-31
LU93066I2 (fr) 2016-07-11
ECSP066947A (es) 2007-01-26
HUS1500058I1 (hu) 2016-01-28
FR16C0029I1 (instruction) 2016-08-26
FIC20170005I1 (fi) 2017-01-13
SG152237A1 (en) 2009-05-29
IL177685A (en) 2013-10-31
FR16C0029I2 (fr) 2017-01-27
EA013157B1 (ru) 2010-02-26
EP1781298B1 (de) 2012-01-04
BRPI0510080A (pt) 2007-10-16
MY148945A (en) 2013-06-14
CY2017014I2 (el) 2017-11-14
NO20065060L (no) 2006-11-21
BE2015C065I2 (instruction) 2024-08-08
EP1781298A1 (de) 2007-05-09
CY1113890T1 (el) 2016-07-27
PE20060462A1 (es) 2006-06-19
KR101287460B1 (ko) 2013-07-23
TWI374739B (en) 2012-10-21
JP2007533683A (ja) 2007-11-22
IL226562A0 (en) 2013-06-27
CA2559699A1 (en) 2005-11-03
KR20130049840A (ko) 2013-05-14
DK1781298T3 (da) 2012-05-07
ZA200606624B (en) 2008-01-08
BRPI0510080B8 (pt) 2021-05-25
SI2422786T1 (sl) 2014-12-31
CY2017014I1 (el) 2017-11-14
SI1781298T1 (sl) 2012-04-30
EP2422786A1 (de) 2012-02-29

Similar Documents

Publication Publication Date Title
NL300779I2 (nl) Combinatie van a) olodaterol, het individuele optische R-isomeer daarvan, mengsels van individuele enantiomeren of racematen, zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, desgewenst in de vorm van solvaten en/of hydraten, en b) een tiotropiumzout; in het bijzonder combinatie van a) olodaterol en zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, en b) tiotropiumbromide, desgewenst in de vorm van een solvaat en/of hydraat; meer in het bijzonder combinatie van a) olodaterolhydrochloride en b) tiotropiumbromide, desgewenst in de vorm van het monohydraat
NL301104I1 (nl) Fedratinib, of een farmaceutisch aanvaardbaar zout daarvan, of een farmaceutisch aanvaardbaar hydraat daarvan, in het bijzonder fedratinibdihydrochloridemonohydraat
NO2017010I2 (no) Dolutegravir eller et farmasøytisk akseptabelt salt eller solvat derav
NL300974I2 (nl) Binimetinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NO2022057I1 (no) Capmatinib or a pharmaceutically acceptable salt thereof
NL301150I2 (nl) setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301042I1 (nl) Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301049I1 (nl) Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NO2018029I1 (no) Alogliptin i kombinasjon med metformin, hver eventuelt i form av et farmasøytisk akseptabelt salt derav
NL300865I1 (nl) Eluxadoline of een farmaceutisch aanvaardbaar zout ervan
NO2020038I1 (no) Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NO2019027I1 (no) kobicistat eller et farmasøytisk akseptabelt salt derav
DK1711481T4 (da) Krystallinsk monohydrat som kinaseinhibitorer
NL300913I2 (nl) Cariprazine, optioneel in de vorm van een zout, waaronder cariprazine hydrochloride
NL300640I2 (nl) Alogliptine of een farmaceutisch aanvaardbaar zout daarvan
NL300937I2 (nl) Niraparib, of een tautomeer daarvan, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder het tosylaat of een hydraat, meer in het bijzonder het tosylaat monohydraat
IL190198A0 (en) N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
SMP201000002B (it) Sali dell'inibitore di chinasi janus (R)-3-(4-(7H-pirrolo[2,3-D]pirimidin-4-IL)-1H-pirazoli-1-IL)-3-ciclopentilpropanonitrile
AR061980A1 (es) Acilanilidas sustituidas y metodos para su utilizacion
ME02688B (me) Hinazolinoni kao inhibitori humane fosfatidilinozitol 3 - kinaze delta
TW200716567A (en) Aspartyl protease inhibitors
DK1789021T4 (da) Forlænget-frigivelse-tabletformulering indeholdende pramipexol eller et farmaceutisk acceptabelt salt deraf
ZA200801351B (en) Sulphonypyrrole hydrochloride salts as histone deacetylases inhibitors
AP2006003705A0 (en) Quinoline derivatives for use as mycobacterial inhibitors
DK2011796T3 (da) Neurogenese-inducer eller terapeutisk middel mod neuropati omfattende alkyletherderivat eller salt deraf